We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Piper
I still agree that your Mcap figures are quite achievable . I only wish I could raise a bit more investment money . Good luck
Thanks Pepesmint. Yes, the fag packet valuation is basically for the company to upscale to full production capacity of over 4 million MTKs per month of all flavours. So some of Mologics Elisa Test, some RTC, some Visitect CD4, maybe other production contracts to be signed in future, who knows but the base case is that if we make a few quid off each MTK produced at full capacity then that level of profit re rates the company up into mid cap territory, in a totally different solar system to where we are now. As long as the massive global market for MTKs continues to grow then the companies future success is very likely.
300M-500M M/cap is very achievable . Looking forward to details on orders and mark up. I believe these will be company changing .
Piper
Don’t forget we have the CD4 HIV lateral as well to consider . The expansion was to accommodate the extra work needed for this as well as for the consortium. See below an extract from an email I had from Omega. It also explains where we are with Mologic....
Abingdon is the lead developer in this project and when required they call on the various skills of the consortium members. As I'm sure you're aware Omega have been working for some time creating a CD4 lateral flow test that can be used in the management of HIV in a point of care setting in harsh environments without the need for refrigeration and so clearly there is expertise they can offer as well manufacturing capacity once developed. Omega has provided their expertise, both physically and in an advisory role.
The site expansion is in readiness for production of the lateral flow test, ensuring they have capacity for existing manufacturing commitment as well as manufacturing for the consortium.
I can't give you details of manufacturing volumes for Mologic. They are still working towards validations from PHE, NHS Scotland and Ireland and once a longer-term supply agreement is finalised we'll announce that via an RNS.
If we don’t want to be so conservative then we can say £4 margin per test so £160Million profit per year at a P/E ratio of 10 which values the company at £1.6Billion and a share price of over £10 but that income would have to be sustained for a few years to achieve that valuation. I’d be very happy with an Mcap of £300-£500Million for now which is very realistic and achievable near term. GLA.
The 4 million tests per month is in the company’s near term expansion plans. Just add up the capacity over two sites...
Hello
Thank you for your message.
Our current capacity for lateral flow tests at Alva is 100,000 tests per week. We are currently in the process of increasing that to 200,000 tests per week and looking at options to further increase to 500,000 tests per week.
Our capacity in Littleport is currently just under 50,000 tests per day. We are currently looking to increase that to 100,000 per day.
We only have two manufacturing sites.
Best wishes
Omega Diagnostics
Pivotal week looming upon us. Baited breathe springs to mind.
Anything could happen to ODX now.
Piper where do you get the 4 million number from, that amount suggests £2 per POC within reason, that’s pretty conservative overall, I think average will be higher, anyway it wouldn’t matter if this came true
Be interesting if at any point we received word from the burnet institute that they had a design freeze ready?? Again they can’t make everything they need in Australia, the design would be exported
No. For ODX to be successful it’s about manufacturing millions of any good product at good margin. Anybody’s test. Doesn’t matter whose test. Just make 4 million per month and sell them and they’re successful. Doesn’t have to be the TTC Test. It isn’t all about the RTC Test.
For ODXto be successful it will be about their product and how they position it within the market.
It is a bonus that they are backed by the RTC, but if the product is right they will be successful regardless.
Key is not rushing me making sure it is a quality and viable product for the global market.
Politics will not affect the success or failure or the return on investment.
Given what’s happened with Dom the wrong un’, BoJo will be at pains to have some positive front page news, and UKRTC could be the ones to provide it.
let’s face it, Friday saw the news that the Roche test isn’t as accurate as first thought, Saturday his puppeteer gets outed for what he his, and Sunday he embarrassed himself and lost any remaining credibility he and his government had.
The UK-RTC test could be his only lifeline, to show they haven’t totalled ballsed this up and have some positive spin. Big question is, are they brave enough to go with the consortium they setup, or will the go with AN-OTHER provider?
Big daily briefing today for ODX & Co today..